Abstract 340P
Background
The optimal follow-up strategy for the detection of relapse in patients with diffuse large B-cell lymphoma (DLBCL) has not been clarified. In this report, we assess the role of laboratory tests and CT for surveillance and investigate the risk factors for recurrence.
Methods
We reviewed the clinical records of patients who achieved CR by PET-CT after received R-CHOP like regimen in our hospital for DLBCL between February 2008 and February 2022. Clinical evaluation post treatment was done every 3-6 months in the first 2 years, and every 6–12 years in the 3 coming years.
Results
A total of 324 patients were eligible for inclusion in this study. The median duration of follow-up for surviving patients was 4.3 years. The cumulative incidence of relapse without death at 2 and 5 years was 13.3% and 21.6%. Overall, 1453 CT scans were carried out through surveillance. The total of 64 patients relapsed within the observation period. Of these, 19 patients were detected to have recurrence on surveillance CT scans. On univariate analysis, ABC-type, extranodal (EN) stites > 1 at diagnosi, and relative dose intensity (RDI) < 90% were risk factors for recurrence. On Fine-Gray regression analysis, ABC-type (HR 2.1, 95% confidence interval [95% CI] 1.1-3.7. p=0.018) and EN sites > 1 at diagnosis (HR 1.8, 95% CI 1.1-3.6. p=0.031) were independent risk factors for recurrence. The area under the curve (AUC) of the receiver operating characteristic (ROC) curve of the surveillance value of soluble interleukin-2 (sIL-2R) (HR 0.81, 95% CI 0.72–0.90) was significantly larger than lactate dehydrogenase (LDH) (0.65, 95% CI 0.55–0.75. p=0.024). While in the normal pretreatment sIL-2R group, the AUC of the ROC curve of sIL2R was small (0.57), however, in the high pretreatment sIL-2R group, the AUC of the ROC curve of sIL2-R (0.83, 95% CI 0.74-0.91) was high. We defined the best cutoff value of the sIL2-R as 607.5 using a ROC curve in the high pretreatment sIL-2R group (Sensitivity 0.63. Specificity 0.88).
Conclusions
Routine surveillance CT scans were of limited value in detecting asymptomatic relapse. ABC-type and EN sites were independent risk factors for recurrence. The measurement of sIL-2R might be useful for surveillance.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
16P - Patient and healthcare practitioner preferences in early-stage triple-negative breast cancer treatment: A discrete choice experiment
Presenter: Jiun-I Lai
Session: Poster Display
Resources:
Abstract
17P - Initial outcomes of the ACT Now PRIME CARE for breast cancer: Prevention of Breast canceR (screening/ stage shifting) utilizing Integrated MobilE Clinics and pAtient Reported online Evaluations and Education
Presenter: Herdee Gloriane Luna
Session: Poster Display
Resources:
Abstract
18P - Optimizing premenopausal HR+ HER2–ve eBC management in India: Insights from expert consensus
Presenter: Anitha Ramesh
Session: Poster Display
Resources:
Abstract
19P - Referral patterns among breast cancer patients in county-level hospitals in China
Presenter: Ping Lu
Session: Poster Display
Resources:
Abstract
20P - Real-world treatment of HER2+ and HR+/HER2- early breast cancer in county areas of China
Presenter: Ping Lu
Session: Poster Display
Resources:
Abstract
21P - Duration of breast cancer trials: Analysis of predicted versus actual completion date
Presenter: Daniëlle Verschoor
Session: Poster Display
Resources:
Abstract
22P - Impact of an online Asian genetic risk calculator on risk perception: Cancer-related distress and uptake of genetic counselling among Malaysian breast cancer patients (The ARiCa Study)
Presenter: HEAMANTHAA Padmanabhan
Session: Poster Display
Resources:
Abstract
23P - Consensus statements and expert recommendations for BRCAm breast cancer in the Asia-Pacific region (STREAM-AP)
Presenter: Soo Chin Lee
Session: Poster Display
Resources:
Abstract
24P - Germline genetic testing for hereditary cancer: A retrospective analysis in a single site referral centre in Malaysia
Presenter: Vivian Lee
Session: Poster Display
Resources:
Abstract
25P - Clinical presentations and prognostication of HER2-low breast cancer in Taiwan
Presenter: Bo-Fang Chen
Session: Poster Display
Resources:
Abstract